雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Present Status and Future Aspect of Chemotherapy and Multi-modality Therapy for Gastric Cancer Toshifusa Nakajima 1 , Toshiharu Yamaguchi 1 , Shigekazu Ohyama 1 , Yasuyuki Seto 1 1Department of Gastrointestinal Tract Surgery, Cancer Institute Hospital Keyword: Gastric cancer , Chemotherapy , Adjuvant and neoadjuvant chemotherapy , Review pp.94-104
Published Date 2005/1/25
DOI https://doi.org/10.11477/mf.1403100010
  • Abstract
  • Look Inside
  • Reference

 The present status of chemotherapy and multimodality therapy for gastric cancer was reviewed comparing Japan and Western countries and followed by discussion for their future use. In Western countries, ECF or DCF is supposedly the standard chemotherapy for advanced gastric cancer after randomized controlled studies (RCT) with FAM, FAMTX, EAP, ELF, or PELF regimens in terms of response rate and survival time. In our country, RCTs are not complete until recent promising regimens with S-1, Taxanes, or CPT-11 are carried out for advanced gastric cancer. A global standard, embracing the best regimens used in both Western countries and Japan, should be established for RCTs.

 Neoadjuvant chemotherapy with recent promising regimens seems to provide a good response and high effectiveness, but survival benefit still awaits future RCT. As a postoperative adjuvant therapy, a certain chemoradiotherapy was proved to produce a significant survival benefit in large-scale RCT, and it has become standard therapy after curative gastrectomy in U.S.A. However, incorporation of this theraphy to our country should be made cautiously because of its different background and surgical technology.


Copyright © 2005, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1219 印刷版ISSN 0536-2180 医学書院

関連文献

もっと見る

文献を共有